Results 191 to 200 of about 4,785,875 (311)
La Memoria de Investigación 2023 del Hospital Universitario Virgen de las Nieves (HUVN) presenta un análisis exhaustivo de la actividad investigadora realizada en el hospital durante el año.
González Flores, Encarnación +2 more
core
ABSTRACT Objective Facioscapulohumeral muscular dystrophy (FSHD) is one of the most debilitating and common muscular dystrophies. Despite its severity, no approved therapy exists for FSHD patients. However, several therapeutic candidates are currently under development, and some have recently entered clinical trials, marking the need for reliable ...
Mustafa Bilal Bayazit +11 more
wiley +1 more source
Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito +8 more
wiley +1 more source
Trends and spatial distribution of low-level viremia among Ugandan children and adolescents, 2014-2023. [PDF]
Lubega JK +8 more
europepmc +1 more source
Oikeusministeriö asetti keväällä 2023 Ahvenanmaan maakunnan hallituksen kanssa työryhmän (Ahvenanmaa-työryhmä 2023) muun muassa valmistelemaan Ahvenanmaan itsehallintolakia koskevan esityksen jatkovalmistelua, jonka tavoitteena on uudistaa ja kehittää ...
core
ABSTRACT Objectives We aimed to determine the frequency of subclinical optic nerve (ON) lesions using MRI, optical coherence tomography (OCT), and visual evoked potentials (VEP) in radiologically isolated syndrome (RIS), and to assess their diagnostic and prognostic significance.
Christine Lebrun‐Frenay +13 more
wiley +1 more source
All‑cause excess mortality in Germany peaked during the late‑2022 influenza period, exceeding peaks during SARS‑CoV‑2 waves (2020-2023). [PDF]
Heudorf U, Kowall B.
europepmc +1 more source

